PL351087A1 - Enos mutations useful for gene therapy and therapeutic screening - Google Patents

Enos mutations useful for gene therapy and therapeutic screening

Info

Publication number
PL351087A1
PL351087A1 PL00351087A PL35108700A PL351087A1 PL 351087 A1 PL351087 A1 PL 351087A1 PL 00351087 A PL00351087 A PL 00351087A PL 35108700 A PL35108700 A PL 35108700A PL 351087 A1 PL351087 A1 PL 351087A1
Authority
PL
Poland
Prior art keywords
gene therapy
therapeutic screening
mutations useful
enos
enos mutations
Prior art date
Application number
PL00351087A
Inventor
William C Sessa
Original Assignee
Univ Yale
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Yale filed Critical Univ Yale
Publication of PL351087A1 publication Critical patent/PL351087A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
    • C12N9/0073—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14) with NADH or NADPH as one donor, and incorporation of one atom of oxygen 1.14.13
    • C12N9/0075—Nitric-oxide synthase (1.14.13.39)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Gynecology & Obstetrics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Reproductive Health (AREA)
  • Plant Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL00351087A 1999-04-16 2000-04-14 Enos mutations useful for gene therapy and therapeutic screening PL351087A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US12955099P 1999-04-16 1999-04-16

Publications (1)

Publication Number Publication Date
PL351087A1 true PL351087A1 (en) 2003-03-24

Family

ID=22440541

Family Applications (1)

Application Number Title Priority Date Filing Date
PL00351087A PL351087A1 (en) 1999-04-16 2000-04-14 Enos mutations useful for gene therapy and therapeutic screening

Country Status (25)

Country Link
US (4) US6900038B2 (en)
EP (1) EP1178722A4 (en)
JP (1) JP2002541829A (en)
KR (1) KR100737945B1 (en)
CN (1) CN100357433C (en)
AU (2) AU774010B2 (en)
BG (1) BG106051A (en)
BR (1) BR0009805A (en)
CA (1) CA2369764A1 (en)
CZ (1) CZ20013427A3 (en)
EE (1) EE200100538A (en)
HK (1) HK1046081B (en)
HR (1) HRP20010797A2 (en)
HU (1) HUP0200799A3 (en)
IL (1) IL145760A0 (en)
MX (1) MXPA01010459A (en)
NO (1) NO20015008L (en)
NZ (1) NZ514305A (en)
PL (1) PL351087A1 (en)
RU (1) RU2257226C2 (en)
SK (1) SK14692001A3 (en)
UA (1) UA76939C2 (en)
WO (1) WO2000062605A1 (en)
YU (1) YU73301A (en)
ZA (1) ZA200108463B (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000062605A1 (en) * 1999-04-16 2000-10-26 Yale University eNOS MUTATIONS USEFUL FOR GENE THERAPY AND THERAPEUTIC SCREENING
CA2489446A1 (en) 2002-06-14 2003-12-24 Wisconsin Alumni Research Foundation Ribonuclease zymogen design
AU2003265461A1 (en) * 2002-08-16 2004-03-03 Cardium Therapeutics Inc. eNOS MUTANTS USEFUL FOR GENE THERAPY
CA2494845A1 (en) * 2002-08-16 2004-02-26 Cardium Therapeutics, Inc. Gene therapy for critical limb ischemia with wild type or mutant enos
GB0226463D0 (en) * 2002-11-13 2002-12-18 Isis Innovation Mimicking the athletic heart
WO2004050126A2 (en) * 2002-12-02 2004-06-17 Anges Mg, Inc. Compositions for treating or preventing angiogenesis-dependent symptoms
WO2006023879A1 (en) * 2004-08-20 2006-03-02 Board Of Regents, The University Of Texas System Screening of agents for activity against ischemic myocardial insults
SG155257A1 (en) * 2004-09-24 2009-09-30 Beth Israel Hospital Methods of diagnosing and treating complications of pregnancy
US7740849B2 (en) * 2004-09-24 2010-06-22 Beth Israel Deaconess Medical Center Use of compounds that bind soluble endoglin and SFLT-1 for the treatment of pregnancy related hypertensive disorders
MX2008015197A (en) * 2006-05-31 2009-06-23 Beth Israel Hospital Methods of diagnosing and treating complications of pregnancy.
US20090286271A1 (en) * 2006-05-31 2009-11-19 Karumanchi Ananth S Methods of Diagnosing and Treating Complications of Pregnancy
EP2326953B1 (en) * 2008-07-22 2018-03-21 Promega Corporation Adp detection based luminescent phosphotransferase or atp hydrolase assay
AU2009324228A1 (en) * 2008-12-04 2011-06-23 Sanofi-Aventis Methods and uses involving Heme binding protein 1
RU2526575C2 (en) * 2012-11-02 2014-08-27 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Московский государственный университет имени М.В. Ломоносова" (МГУ) Method for improving immunosuppressive properties of mesenchymal stromal cells of fatty tissue
US9677117B2 (en) 2014-10-08 2017-06-13 Promega Corporation Bioluminescent succinate detection assay
CN107802826B (en) * 2017-10-26 2020-02-18 首都医科大学宣武医院 Application of eNOS mutants in promoting angiogenesis
CN116790603B (en) * 2023-08-18 2023-10-31 成都中科奥格生物科技有限公司 sgRNA and CRISPR/Cas9 vector as well as construction method and application thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5498539A (en) * 1992-07-02 1996-03-12 Daiichi Pharmaceutical Co., Ltd. Bovine endothelial nitric oxide synthase nucleic acids
US5658565A (en) * 1994-06-24 1997-08-19 University Of Pittsburgh Of The Commonwealth System Of Higher Education Inducible nitric oxide synthase gene for treatment of disease
DE4411402A1 (en) * 1994-03-31 1995-10-05 Juergen Schrader DNA expression vectors for use in gene therapy treatment of vascular diseases
FR2722507B1 (en) * 1994-07-12 1996-08-14 Rhone Poulenc Rorer Sa ADENOVIRUS COMPRISING A GENE ENCODING NO SYNTHASE
US5968983A (en) * 1994-10-05 1999-10-19 Nitrosystems, Inc Method and formulation for treating vascular disease
US5837534A (en) * 1995-11-14 1998-11-17 The Board Of Regents Of The University Of Texas System Smooth muscle 22α promoter, gene transfer vectors containing the same, and method of use of the same to target gene expression in arterial smooth muscle cells
EP1117426B1 (en) * 1998-10-02 2005-12-07 Caritas St. Elizabeth's Medical Center of Boston, Inc. Akt compositions for enhancing survival of cardiomyocytes
DE60039677D1 (en) * 1999-03-19 2008-09-11 Aventis Pharma Inc AKT-3 NUCLEIC ACID, POLYPEPTIDES, AND ITS USE
WO2000062605A1 (en) * 1999-04-16 2000-10-26 Yale University eNOS MUTATIONS USEFUL FOR GENE THERAPY AND THERAPEUTIC SCREENING
NZ516054A (en) * 1999-06-11 2004-04-30 Aventis Pharm Prod Inc Induction of vascular endothelial growth factor (VEGF) by the serine/threonine protein kinase AKT

Also Published As

Publication number Publication date
WO2000062605A1 (en) 2000-10-26
US20030049823A1 (en) 2003-03-13
ZA200108463B (en) 2003-01-15
US7888089B2 (en) 2011-02-15
CZ20013427A3 (en) 2002-03-13
NO20015008D0 (en) 2001-10-15
BR0009805A (en) 2002-01-15
HRP20010797A2 (en) 2003-02-28
HUP0200799A3 (en) 2004-11-29
IL145760A0 (en) 2002-07-25
EP1178722A1 (en) 2002-02-13
US6900038B2 (en) 2005-05-31
AU2004210533A1 (en) 2004-11-04
US20090246183A1 (en) 2009-10-01
RU2257226C2 (en) 2005-07-27
YU73301A (en) 2004-07-15
BG106051A (en) 2002-06-28
JP2002541829A (en) 2002-12-10
US20110173711A1 (en) 2011-07-14
HK1046081B (en) 2008-09-05
MXPA01010459A (en) 2003-08-20
US20040253685A1 (en) 2004-12-16
CA2369764A1 (en) 2000-10-26
HUP0200799A2 (en) 2002-06-29
KR100737945B1 (en) 2007-07-13
AU774010B2 (en) 2004-06-10
CN1347283A (en) 2002-05-01
CN100357433C (en) 2007-12-26
SK14692001A3 (en) 2002-09-10
HK1046081A1 (en) 2002-12-27
KR20010110770A (en) 2001-12-13
UA76939C2 (en) 2006-10-16
EE200100538A (en) 2002-12-16
NO20015008L (en) 2001-12-07
AU4237800A (en) 2000-11-02
NZ514305A (en) 2004-01-30
EP1178722A4 (en) 2003-03-05

Similar Documents

Publication Publication Date Title
PL351087A1 (en) Enos mutations useful for gene therapy and therapeutic screening
IL144954A0 (en) Quinazolines and therapeutic use thereof
AU6528800A (en) Methods and apparatuses for radiation treatment
IL132419A0 (en) Image-guided thoracic therapy and apparatus therefor
HUP0201966A3 (en) Methods of treatment and drug screening methods
GB9824160D0 (en) Heterocyclic compounds and their therapeutic use
GB9812550D0 (en) Tumour therapy and imaging
IL141501A0 (en) Alginate capsules for use in the treatment of brain tumour
AU5672000A (en) Method for detecting the effect of different chemotherapeutic agents and/or radiation therapy in malignant diseases and method for selecting more effective therapeutic agents for the therapy thereof
GB9924981D0 (en) Gene therapy
GB9900009D0 (en) Gene therapy
IL132531A0 (en) Detection and therapy of tumors
GB0406539D0 (en) Gene therapy
IL127826A0 (en) Restenosis drug therapy
IL148674A0 (en) Modulation of enos activity and therapeutic uses thereof
HUP0105469A3 (en) Therapeutic drugs comprising pyrroloazepines for treating intermittent claudication
AU6404698A (en) Treatment methods for obtaining therapeutic products and resulting products
EP1150967A4 (en) Therapeutic compounds and methods
GB9920837D0 (en) Gene therapy
GB9910587D0 (en) Gene therapy
GB9727456D0 (en) Conjugate compounds useful for non-viral gene therapy and methods for the production thereof
GB9905307D0 (en) Therapy and use of compounds in therapy
AU2918199A (en) Tumour imaging and therapeutic agents
GB9901505D0 (en) Therapeutic treatment
GB9918785D0 (en) Therapeutic treatment

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)